Exceptional Response to Crizotinib in an MET-Amplified Triple-Negative Breast Tumor
- 1 November 2017
- journal article
- case report
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 1 (1) , 1-6
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Crizotinib: from discovery to accelerated development to front-line treatmentAnnals of Oncology, 2016
- Predictive role of the overexpression for CXCR4, C-Met, and VEGF-C among breast cancer patients: A meta-analysisThe Breast, 2016
- Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site MutationClinical Lung Cancer, 2015
- Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET InhibitorsCancer Discovery, 2015
- MET Mutation Associated with Responsiveness to CrizotinibJournal of Thoracic Oncology, 2015
- MET-Mutated NSCLC with Major Response to CrizotinibJournal of Thoracic Oncology, 2015
- Comprehensive molecular profiling of lung adenocarcinomaNature, 2014
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Targeting MET in cancer: rationale and progressNature Reviews Cancer, 2012
- Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET AmplificationJournal of Thoracic Oncology, 2011